Sanofi acquired Tidal Therapeutics, a preclinical stage biotech company with a novel mRNA-platform for reprogramming of immune cells, for $160 million upfront and up to $310 million in milestones. The new technology platform expands Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, with potential in other disease areas.     “We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient pop...